ASO Visual Abstract: Resectable Pancreatic Cancer with CA19-9 > 500 U/mL—A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy
本文未提供摘要,请点击“查看全文”查看完整内容。